Victory Capital Management
INSY

Victory Capital Management’s Insys Therapeutics, Inc. INSY Stock Holding History

Victory Capital Management’s Portfolio INSY Stock Details INSY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-966
Closed -$12K – 1903
2017
Q2 		$12K Buy
966
+17
+2% +$201 ﹤0.01% 1795
2017
Q1 		$10K Sell
949
-2,711
-74% -$28.9K ﹤0.01% 1791
2016
Q4 		$34K Sell
3,660
-13
-0.4% -$147 ﹤0.01% 1735
2016
Q3 		$43K Buy
3,673
+360
+11% +$5.47K ﹤0.01% 1721
2016
Q2 		$43K Buy
3,313
+1,099
+50% +$16K ﹤0.01% 1547
2016
Q1 		$35K Buy
2,214
+30
+1% +$570 ﹤0.01% 1531
2015
Q4 		$63K Sell
2,184
-8
-0.4% -$222 ﹤0.01% 1503
2015
Q3 		$62K Buy
2,192
+222
+11% +$8.17K ﹤0.01% 1424
2015
Q2 		$70K Buy
+1,970
New +$61.4K ﹤0.01% 1361

Other funds holding INSY

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $299B AUM 28.69% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
FHAM
Folger Hill Asset Management New York $16.5M AUM 19.96% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Victory Capital Management's INSY Position: Q3 2017 in Review

Victory Capital Management sold out of Insys Therapeutics, Inc. (INSY) in Q3 2017, closing a stake of 966 shares — an estimated $12K sold.

Victory Capital Management first reported a position in INSY in Q2 2015 and held it in 9 quarters. The position peaked at $70K in Q2 2015. 116 funds tracked by Wall St. Rank hold INSY as of Q3 2017.

  • Victory Capital Management reported no remaining Insys Therapeutics, Inc. position as of Q3 2017 after selling out during the quarter.
  • Victory Capital Management sold 966 Insys Therapeutics, Inc. shares in Q3 2017, an estimated $12K.
  • Victory Capital Management first reported a position in Insys Therapeutics, Inc. in Q2 2015 and held it in 9 quarters.
  • Victory Capital Management's Insys Therapeutics, Inc. position peaked at $70K in Q2 2015.
  • 116 funds tracked by Wall St. Rank held Insys Therapeutics, Inc. as of Q3 2017.

Based on Victory Capital Management's 13F filing for Q3 2017, filed 27 Oct 2017.